CALRX


Associated tags: Public Policy, Insulin, Civica, Pharmaceutical industry, Insulin aspart, Patient, Insulin lispro, Inc., Hospitals, Government, Healthcare Reform, Diabetes, Health, Managed Care, Local, State, Pharmaceutical, Insulin glargine

Locations: PAN, CALIFORNIA

California Selects Civica Rx as Its Insulin Manufacturing Partner

Retrieved on: 
Saturday, March 18, 2023
Public Policy, Government, Pharmaceutical, State, Local, Managed Care, Health, Diabetes, Healthcare Reform, Hospitals, Insulin, Inc., Partnership, Insulin lispro, Patient, Risk, Insulin aspart, Pharmaceutical industry, Civica, Insulin glargine

Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.

Key Points: 
  • Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work.
  • “California’s partnership with Civica is a game changer,” said California Governor Gavin Newsom.
  • Civica and CalRx have the mutual goal of ensuring access to affordable insulins that have single, low transparent prices.
  • The next phase of this partnership is assessing options for the standup of an insulin manufacturing facility in California and further efforts to disrupt the insulin market and provide additional benefits for patients who depend on this life saving drug.